Abstract
Objetivo
Conocer el grado de adecuación de la profilaxis tromboembólica (PTE) en un grupo de pacientes con fibrilación auricular crónica, en el ámbito de la atención primaria
Diseño
Estudio descriptivo, transversal y multicéntrico
Emplazamiento
El estudio se ha realizado en 3 centros de atención primaria de carácter urbano de Madrid
Participantes
Se ha incluido a todos los pacientes registrados, hasta abril de 2001, con el diagnóstico de fibrilación auricular crónica (n = 274). Se ha excluido a los pacientes sin historia clínica y a los portadores de prótesis valvular
Mediciones principales
Se han recogido variables demográficas, existencia de factores de riesgo de embolia, presencia de contraindicaciones para la anticoagulación oral y tipo de profilaxis tromboembólica
Resultados
Se evaluó a un total de 274 pacientes. La media de edad ± desviación estándas fue de 75 ± 9 años y el 52% eran mujeres. El 82% de los pacientes tenía al menos un factor de riesgo tromboembólico. El tipo de PTE más frecuentemente empleada fue la anticoagulación oral. Un 45% de los pacientes no recibía una adecuada PTE. Se encontró un 13,5% de pacientes con riesgo embolígeno sin ningún tipo de PTE
Conclusiones
Existe un alto porcentaje de pacientes con fibrilación auricular crónica y alto riesgo de embolia que no reciben una adecuada PTE, en ausencia de contraindicaciones para la anticoagulación oral. Existe un amplio campo de mejora, al alcance de los profesionales
Palabras clave: Fibrilación auricular, Anticoagulantes, Aspirina
Abstract
Objective
To find just how suitable thromboembolism prophylaxis (TEP) is in a group of patients with chronic auricular fibrillation belonging to the primary care environment
Design
Cross-sectional and descriptive multicentre study
Setting
The study was performed at 3 urban primary care centres in Madrid
Participants
All the patients recorded up to April 2001 with the diagnosis of chronic auricular fibrillation (n=274) were included. Patients with no clinical history or who had a valve prosthesis were excluded
Main measurements
Demographic variables, existence of factors of risk of embolism, presence of counter-indications for oral anticoagulants, and the kind of thromboembolic prophylaxis taken were collected
Results
A total of 274 patients were evaluated. Average age was 75 (SD, 9) and 52% were women. 82% of patients had at least one factor of risk of thromboembolism. The most commonly used kind of TEP was oral anti-coagulants. 45% of patients did not receive suitable TEP. 13.5% of patients at risk of embolism and who had no kind of TEP were found
Conclusions
There is a high percentage of patients with chronic auricular fibrillation and a high risk of embolism, who do not receive adequate TEP, in the absence of counter-indications to taking oral anticoagulants.There is great scope for improvement, which is within professionals' possibilities
Key words: Auricular fibrillation, Anticoagulants, Aspirin
Bibliografía
- 1.Wolf P.A., Dawber T.R., Thomas H.E., Jr, Kannel W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973–977. doi: 10.1212/wnl.28.10.973. [DOI] [PubMed] [Google Scholar]
- 2.Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988. doi: 10.1161/01.str.22.8.983. [DOI] [PubMed] [Google Scholar]
- 3.Petersen P., Boysen G., Godtfredsen J., Andersen E., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–178. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
- 4.Stroke Prevention in Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527–539. doi: 10.1161/01.cir.84.2.527. [DOI] [PubMed] [Google Scholar]
- 5.The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511. doi: 10.1056/NEJM199011293232201. [DOI] [PubMed] [Google Scholar]
- 6.Connolly S.J., Laupacis A., Gent M., Roberts R.S., Cairns J.A., Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349–355. doi: 10.1016/0735-1097(91)90585-w. [DOI] [PubMed] [Google Scholar]
- 7.Ezekowitz M.D., Bridgers S.L., James K.E., Carliner N.H., Colling C.L., Gornick C.C. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412. doi: 10.1056/NEJM199211123272002. [DOI] [PubMed] [Google Scholar]
- 8.Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised clinical trials. Arch Intern Med. 1994;154:1449–1457. [PubMed] [Google Scholar]
- 9.Heras M., Fernández A., Gómez J.A., Iriarte J.A., Lidón R.M., Pérez F. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Rev Esp Cardiol. 1999;52:801–820. doi: 10.1016/s0300-8932(99)75009-8. [DOI] [PubMed] [Google Scholar]
- 10.Martín E., Salgado F., Sánchez A., Martos F., González J.A., Fuentes T. Valoración del tratamiento antitrombótico en pacientes con fibrilación auricular crónica no valvular. Aten Primaria. 1998;22:172–175. [PubMed] [Google Scholar]
- 11.Albers G.W., Yim J.M., Belew K.M., Bittar N., Hattemer C.R., Phillips B.G. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156:2311–2316. [PubMed] [Google Scholar]
- 12.Pérez I., Melbourn A., Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart. 1999;82:570–574. doi: 10.1136/hrt.82.5.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Brotons C., Moral I., Antón J.J., Cobos M., Cucurrull E., Gallego C. Tratamiento preventivo de la fibrilación auricular no reumática: de la eficacia de los ensayos clínicos a la efectividad en la práctica clínica. Aten Primaria. 1997;20:367–371. [PubMed] [Google Scholar]
- 14.Laupacis A., Alberrs G.W., Dalen J.E., Dunn M.I., Jacobson A.K., Singer D.E. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579–589. doi: 10.1378/chest.114.5_supplement.579s. [DOI] [PubMed] [Google Scholar]
- 15.Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;3:687–691. [PubMed] [Google Scholar]